

Table 14.2/1  
Progression-Free Survival by Remission Status  
Randomized Subjects

	2nd remission		3rd remission		Overall	
	Placebo (N=26)	CMP-135 (N=26)	Placebo (N=6)	CMP-135 (N=7)	Placebo (N=32)	CMP-135 (N=33)
No. of Subjects	26	26	6	7	32	33
No. of Subjects with an event (%)	15 (57.7%)	12 (46.2%)	3 (50.0%)	3 (42.9%)	18 (56.3%)	15 (45.5%)
Earliest contributing event:						
Disease Progression	15	12	3	3	18	15
Death	.	.	.	.	.	.
No. of Subjects without an event (%)	11 (42.3%)	14 (53.8%)	3 (50.0%)	4 (57.1%)	14 (43.8%)	18 (54.5%)
Progression Free Survival (Months)						
Median	5.6	7.7	7.4	5.6	5.8	7.7
(95% CI)	(3.78, 7.43)	(5.59, NA)	(2.07, NA)	(3.48, NA)	(3.88, 7.43)	(5.59, NA)
25th-75th percentile	(3.6, NA)	(5.3, 13.3)	(5.8, NA)	(5.6, NA)	(3.6, NA)	(5.6, 13.3)
Minimum-maximum	0.8 - 9.2+	1.1 - 13.3+	2.1 - 12.9+	1.9 - 9.2+	0.8 - 12.9+	1.1 - 13.3+
Unstratified Analysis						
Hazard ratio (relative to placebo)		0.654		1.177		0.730
(95% CI)		(0.30, 1.44)		(0.23, 5.96)		(0.36, 1.47)
p-value (relative to placebo)						
Log-rank		0.2890		0.8440		0.3857
Wilcoxon		0.3815		0.7768		0.4234